Live feed10:30:00·28dPRReleasevia QuantisnowCelldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026ByQuantisnow·Wall Street's wire, on your screen.CLDX· Celldex Therapeutics Inc.Health Care
